Blog
RSS FeedPosted by Michael Wonder on 20 Nov 2023
NICE gets ready to assess new dementia treatments
20 November 2023 - NICE’s methods and processes for evaluating new treatments for use in the NHS are appropriate for the ...
Posted by Michael Wonder on 16 Nov 2023
Updates to the HTA Policy and Methods Review Reference Committee (16 November 2023)
16 November 2023 - Two more documents are now available. ...
Posted by Michael Wonder on 16 Nov 2023
New treatment for advanced prostate cancer added to the PBS
16 November 2023 - Prostate cancer is one of the most commonly diagnosed cancer in Australia. ...
Posted by Michael Wonder on 15 Nov 2023
Early benefit assessment: meaningful RCTs are also feasible in late oncological treatment lines
15 November 2023 - Two randomised controlled studies in the third and fourth lines for colorectal and breast cancer each show ...
Posted by Michael Wonder on 15 Nov 2023
Lutetium Lu 177 vipivotide tetraxetan for the treatment of patients with metastatic PSMA positive hormone-relapsed prostate cancer after two or more treatments
15 November 2023 - NICE has published final evidence-based recommendations on the use of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) ...
Posted by Michael Wonder on 14 Nov 2023
DUSC utilisation analysis public release documents (June 2023)
14 November 2023 - The utilisation analysis public release documents from the June 2023 DUSC meeting are now available. ...
Posted by Michael Wonder on 13 Nov 2023
Informing real-time decisions with post-market drug evidence
10 November 2023 - It’s been one year since CADTH launched the Post-Market Drug Evaluation (PMDE) Program to provide decision-makers with ...
Posted by Michael Wonder on 13 Nov 2023
SMC - November 2023 decisions
13 November 2023 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...
Posted by Michael Wonder on 13 Nov 2023
Outcome statement - September 2023 DUSC meeting
13 November 2023 - The Outcome Statement from the September 2023 DUSC meeting is now available. ...
Posted by Michael Wonder on 13 Nov 2023
PHARMAC calls for applications for medicines for rare disorders
13 November 2023 - PHARMAC is calling for applications for medicines to treat rare disorders. ...
Posted by Michael Wonder on 10 Nov 2023
Public Summary Documents – July 2023 PBAC meeting (round 2)
10 November 2023 - The Public Summary Documents (first time decisions not to recommend and deferrals) from the July 2023 ...
Posted by Michael Wonder on 09 Nov 2023
What next for PHARMAC boss after 'sick, sneering' remarks about Rachel Smalley?
10 November 2023 - PHARMAC’s CEO has managed to survive scrutiny from her board over sneering remarks made about broadcaster ...
Posted by Michael Wonder on 09 Nov 2023
Paddy Gower has issues: blind, solo mum desperate for PHARMAC to fund life-changing medicine so she can see her kids
8 November 2023 - We sat in a field of wild daisies. Bright white and yellow against a backdrop of ...
Posted by Michael Wonder on 09 Nov 2023
PHARMAC asked to reconsider funding RSV drug for at risk babies
9 November 2023 - Paediatricians and neonatal experts are pleading with PHARMAC to rethink its decision to stop funding a ...
Posted by Michael Wonder on 09 Nov 2023
Updates to the HTA Policy and Methods Review Reference Committee (9 November 2023)
9 November 2023 - Two more documents are now available. ...